Prevenar 13 (Pneumococcal 13-valent Conjugate Vaccine), from Pfizer, has been granted approval in Japan for the prevention of Pneumococcal Disease...
Pfizer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) approved a...
The European Commission approved an expanded indication for the use of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), from...
Pfizer has announced the publication of findings from its Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) in the March 19...
Pfizer has announced that the European Medicines Agency (EMA) has accepted Pfizer�s application seeking to expand the indication for Prevenar...
Pfizer Inc. announced that the European Commission approved an expanded indication for the use of Prevenar 13 (pneumococcal polysaccharide conjugate...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that the...
Active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to 17 years of age. Active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in adults ≥18 years of age and the elderly. See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes. The use of Prevenar 13 should be determined on the basis of official recommendations taking into consideration the risk of invasive disease and pneumonia in different age groups, underlying comorbidities as well as the variability of serotype epidemiology in different geographical areas.
The European Commission has approved the pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) from Pfizer for...
Active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes. Apexxnar should be used in accordance with official recommendations.